Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biogen -- Ignore unavailable to you. Want to Upgrade?

To: William Partmann who wrote (1196)	1/13/2000 7:59:00 PM
From: Harold Engstrom	Read Replies (1) \| Respond to of 1686

(Warning, this is a mild rant!) Biogen continues to grow revenues at a good clip, and now the president has gone on record with a prediction of 20% earnings growth for 2000. Coupled with next year's likely launch of Amevive, Biogen appears in good shape. The stalling of the VLA4 and Antova programs are an issue, as the pipeline is less promising than it was 3 months ago. Not a big fan of the SSB analyst: her downgrade seems vacuous. If you are going to downgrade something, then at least have a plausible reason. There are a few biotech companies, even now, worth buying. What separates Biogen from the field? While conceding that I lightened up considerably 3 months ago in order to diversify, I also still consider Biogen a strong, conservatively managed company with excellent science and infrastructure. Biogen has real and growing earnings, lots of cash, and these things are complimented by a focus on long-term goals. I sure wish CBS MarketWatch would call someone with something substantial to say instead of relying on someone with a PR machine for words to fill a story.